title: Recurring structural chromosome abnormalities in peripheral blood lymphocytes of patients with mycosis fungoides/Sézary syndrome.
abstract: Cytogenetic analysis was performed on peripheral blood lymphocyte cultures from 19 patients with mycosis fungoides (MF)/Sézary syndrome (SS) stimulated with either phytohemagglutinin, a conventional mitogen, or a combination of interleukin-2 (IL-2) plus IL-7. The use of both PHA-stimulated and IL-2 plus IL-7-stimulated cultures enhanced the ability to identify clonal abnormalities. Clonal abnormalities were observed in 11 patients (53%) including one with monosomy for the sex chromosome as the sole abnormality. Five of the 11 patients with clonal abnormalities had normal peripheral white blood cell counts, indicating detectability of clones in the absence of frankly leukemic disease. The presence of clonal abnormalities correlated with advanced stage disease and a significantly reduced survival duration from the time of cytogenetic studies. Clonal abnormalities involving chromosomes 1 and 8 were observed in six cases. In five cases with aberrations of chromosome 1, loss of material involved the region between 1p22 and 1p36. In an additional case, a reciprocal translocation involving 1p33 was observed. Clonal abnormalities involving chromosomes 10 and 17 were observed in 5 cases, clonal abnormalities involving chromosome 2 in 4 cases, and clonal abnormalities involving chromosomes 4, 5, 6, 9, 13, 15, 19, and 20 in 3 cases. In 2 cases a der(8)t(8;17)(p11;q11) was observed. Regions of the genome that encode T-cell receptors were not involved in abnormalities. The region between 1p22 and 1p36 is identified as a region of the genome that requires detailed analysis toward the identification of potential gene(s) involved in the process of malignant transformation and/or progression in MF/SS.
authors.affiliation: Department of Obstetrics/Gynecology, Northwestern University Medical School, Chicago, IL 60611, USA.
authors.forename: M
authors.initials: M
authors.lastname: Thangavelu
authors.forename: W G
authors.initials: WG
authors.lastname: Finn
authors.forename: K K
authors.initials: KK
authors.lastname: Yelavarthi
authors.forename: H H
authors.initials: HH
authors.lastname: Roenigk
authors.forename: E
authors.initials: E
authors.lastname: Samuelson
authors.forename: L
authors.initials: L
authors.lastname: Peterson
authors.forename: T M
authors.initials: TM
authors.lastname: Kuzel
authors.forename: S T
authors.initials: ST
authors.lastname: Rosen
mesh_terms: D000328:Adult; D000368:Aged; D002471:Cell Transformation, Neoplastic; D002869:Chromosome Aberrations; D002871:Chromosome Banding; D025063:Chromosome Disorders; D003582:Cytogenetics; D005260:Female; D006801:Humans; D007621:Karyotyping; D007958:Leukocyte Count; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000276:immunology / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000235:genetics* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D011379:Prognosis; D012729:Sex Chromosome Aberrations; D012751:Sezary Syndrome / Q000235:genetics* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D012878:Skin Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D016019:Survival Analysis; D013997:Time Factors